Recombinant Human Tumor necrosis factor receptor superfamily member 13B protein (TNFRSF13B), partial (Active)

In Stock
Code CSB-AP002301HU
Size $142
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

>95% as determined by SDS-PAGE.
Less than 1.0 EU/μg as determined by LAL method.
Fully biologically active when compared to standard. The biological activity is determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 ug/ml.
Target Names
Uniprot No.
Research Area
Alternative Names
TNFRSF13B; TACI; Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD antigen CD267
Homo sapiens (Human)
Expression Region
Complete Sequence
Mol. Weight
18.0 kDa
Protein Length
Tag Info
Lyophilized powder
Lyophilized from a 0.2 µm filtered PBS, pH 7.4
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
5-10 business days
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

This Recombinant Human TNFRSF13B (CD267) protein is a valuable tool for cancer research. TNFRSF13B, also known as Transmembrane activator and CAML interactor (TACI), is a member of the tumor necrosis factor receptor superfamily, playing a crucial role in immune regulation and B-cell development.

Produced using E. coli expression system, our protein covers amino acids 1 to 160, representing a partial length of the TNFRSF13B sequence. It is tag-free, ensuring its native conformation and eliminating any potential interference in downstream applications. With a purity exceeding 95% and minimal endotoxin contamination, our TNFRSF13B protein guarantees reliable and consistent results.

Experience its full biological activity when compared to standard, as demonstrated by its ability to block human BAFF-induced T2B cell survival. With a concentration range of 1.0-3.0 µg/ml, our protein shows its potency in cancer-related studies. The lyophilized powder form ensures easy handling and storage, providing convenience in your research endeavors.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
Gene References into Functions
  1. Expression patterns of BAFF and its receptor TACI differ according to lupus nephritis class. PMID: 29087261
  2. p.G76S gain-of-function mutation on the TNFRSF13B gene is responsible for familial or sporadic immune thrombocytopenia. PMID: 28834165
  3. BAFF-induced processing of BAFFR regulates BAFF-mediated B cell responses in a TACI-dependent manner. PMID: 28249164
  4. results suggest that TACI A181E heterozygosity results in TACI haploinsufficiency with increased susceptibility to pneumococcal infection PMID: 27609654
  5. genetic polymorphism is associated with hypogammaglobulinemia and systemic lupus erythematosis in a family with common variable immunodeficiency disorder PMID: 26623716
  6. 11% of common variable immunodeficiency patients and 13% of antibody deficiency syndromes patients carried at least one mutated TNFRSF13B allele. PMID: 27123465
  7. serum levels not associated with disease activity in MPO-ANCA-associated renal vasculitis PMID: 25567522
  8. In this review, we aim at giving an insight into the genetics underlying the CVID and particularly at outlining the role of TACI and its relative contribution to the development of CVID-like phenotypes in human. PMID: 26096648
  9. C104R mutation was associated with common variable immunodeficiency and IgG subclass deficiency. PMID: 26727773
  10. TNFRSF13B hemizygosity does not recapitulate autoimmune features of common variable immune deficiency -associated C104R and A181E TNFRSF13B mutations, which likely encode dominant negative products, but instead reveals selective TACI haploinsufficiency at later stages of B-cell development. PMID: 26100089
  11. Common variable immune deficiency patients with heterozygous mutations in TACI alleles increase susceptibility to autoimmune diseases. PMID: 25866827
  12. The study demonstrated that there is a remarkable interindividual variability of TACI expression in chronic lymphocytic leukemia, although the majority of patients display low to undetectable TACI. PMID: 25950010
  13. Variants of TNFRSF13B were associated with common variable immunodeficiency. PMID: 26122175
  14. only Transmembrane Activator and CAML Interactor (TACI) correlates with the MMC's capability to ligate BAFF. Additionally, the level of expression of TACI correlates with the level of the MMC's BM dependency PMID: 25723853
  15. Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. PMID: 25301447
  16. Although the transcriptional controls for alternative splicing of TACI isoforms remain unknown, differential signals via isoforms may control plasma-cell generation. PMID: 25631768
  17. In conclusion, we confirmed the prognostic significance of soluble BLyS levels with regard to TFT in CLL patients, and, more importantly, we showed for the first time that sTACI is a powerful prognostic marker, related to parameters of disease activity PMID: 25162001
  18. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation. PMID: 25505277
  19. genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
  20. TNFRSF13B/TACI defects alone do not result in CVID but may be also found frequently in distinct clinical phenotypes, including benign lymphoproliferation and IgG subclass deficiencies. PMID: 23956760
  21. TACI mutations enables autoimmune complications in common variable immune deficiency . PMID: 24051380
  22. Intracellular and extracellular TACI expression was defective for B cells of all subjects with mutations. PMID: 23237420
  23. A significant association of TNFRSF13B gene mutations was observed in common variable immunodeficiency patients. PMID: 22884984
  24. Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. PMID: 23225259
  25. Segregation analysis of a kindred shows that inheriting single or double copy of the Cys104Arg mutation does not necessarily consign an individual to common variable immunodeficiency (CVID). PMID: 22983507
  26. Two pediatric Italian male siblings were affected with hypogammaglobulinemia and recurrent respiratory and gastrointestinal infections in association with a novel compound heterozygous I87N/C104R TACI mutation. PMID: 22627058
  27. Three SNPs located in TNFRSF13B on 17p11.2 or nearby were significantly associated with IgG level. PMID: 22673310
  28. Data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood. PMID: 22697072
  29. the identification of two novel mutations in TNFRSF13B, including one, S231R, affecting the highly conserved THC domain PMID: 22076597
  30. We conclude that mutations in TACI are the contributing factors for asthma symptoms in Swedish children, although the mechanisms still remain elusive. PMID: 21850030
  31. Our data provide further evidence that TNFRSF13B/TACI alterations are not causative of common variable immunodeficiency PMID: 21547394
  32. Signals from TLR9, TACI, and CD40 are integrated to promote B-cell activation and differentiation. PMID: 21741080
  33. primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and TACI PMID: 21687682
  34. We have examined the function of TACI coding variants that have been described in patients with common variable immunodeficiency PMID: 21419480
  35. In patients with Smith-Magenis syndrome with only 1 TACI allele, we found decreased B-cell expression of TACI, reduced binding of a proliferation-inducing ligand, and decreased TACI-induced expression of activation-induced cytidine deaminase mRNA. PMID: 21514638
  36. mutations result in impaired B cell response through haploinsufficiency PMID: 20889194
  37. TACI expression on CD19+ B cells was up-regulated in patients with lupus nephritis PMID: 20974656
  38. MyD88 controls a B cell-intrinsic, TIR-independent, TACI-dependent pathway for immunoglobulin diversification PMID: 20676093
  39. the TNFRSF13B A181E mutation is associated with a very heterogeneous clinical presentation along with variability in B-cell numbers and amount of TACI protein on memory B cells in Common Variable ImmunoDeficiency PMID: 20156508
  40. novel mutations identified in this study support the notion of a crucial role for TACI in B cell differentiation PMID: 19629655
  41. Expression of BCMA, TACI, and BAFF-R by multiple myeloma cells support cell growth and survival. PMID: 14512299
  42. TACI(hi) myeloma cells displayed a mature plasma cell gene signature, indicating dependence on the BM environment. In contrast, the TACI(lo) group had a gene signature of plasmablasts, suggesting an attenuated dependence on the BM environment PMID: 15827134
  43. 4 of 19 unrelated individuals with common variable immunodeficiency and 1 of 16 individuals with IgA deficiency had a missense mutation in one allele of TNFRSF13B PMID: 16007086
  44. identified homozygous and heterozygous mutations in TNFRSF13B, encoding TACI, in 13 individuals with common variable immunodeficiency PMID: 16007087
  45. Review. Short-lived antibody forming cell populations and their proliferating progenitors express a TACI-predominant signature. PMID: 16919470
  46. The TACI inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. PMID: 16960154
  47. simultaneous binding of TACI and HSPG on B cells with APRIL is crucial for IgA production PMID: 17119122
  48. TACI-specific signaling inhibits both B cell activating factor of the TNF family receptor (BAFF-R) and CD40-enhanced antibody production from peripheral blood B cells in vitro, although TACI-specific signaling directly induces mild B cell apoptosis. PMID: 17154264
  49. This review defines the exact contribution of TACI receptor stimulation by specific triggers in vitro, enabling us to better understand the complex, context-dependent responses initiated by TACI in vivo. PMID: 17171762
  50. Role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. PMID: 17392797

Show More

Hide All

Involvement in disease
Immunodeficiency, common variable, 2 (CVID2); Immunoglobulin A deficiency 2 (IGAD2)
Subcellular Location
Membrane; Single-pass type III membrane protein.
Tissue Specificity
Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
Database Links

HGNC: 18153

OMIM: 240500

KEGG: hsa:23495

STRING: 9606.ENSP00000261652

UniGene: Hs.158341

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To